BRIEF—Lumicef submitted for new indication in Japan

Japanese drugmaker Kyowa Kirin has submitted to broaden the Japanese label for Lumicef (brodalumab), to include the treatment of the uncommon autoimmune disorder palmoplantar pustulosis (PPP).

If approved, the therapy will be offered to people who have not responded well to existing treatment options. The submission is backed by positive results from a Phase III trial.

R&D head Yoshifumi Torii said: “We are profoundly pleased to submit Lumicef as the first IL-17 pathway inhibitor to treat PPP.”

He added: “Symptoms in the palms and soles of the hands and feet interfere with PPP patients' daily lives, so new therapeutic treatments are desired to improve their quality of life.”